Chih-YiLiaoChih-Yi Liao41.7886000000000087.598699999999993565Liao, Chih-YiAssistant Professorplugins:TwitterTwitterprns:coAuthorOfcoauthor ofprns:emailEncryptedemail addressprns:endDateend dateFaculty Rankprns:fullNamefull nameprns:hasAuthorListauthor listprns:hasFacultyRankhas faculty rankprns:hasNetworkhas networkprns:hasPublicationVenuepublished inprns:informationResourceReferenceinformation resource referenceprns:isPrimaryPositionis primary positionprns:latitudelatitudeprns:longitudelongitudeprns:mainImagephotoprns:maxWeightmaximum weightprns:medlineTAjournal title abbreviationprns:meshDescriptorUIMeSH DescriptorUIprns:meshSemanticGroupNameMeSH semantic group nameprns:minWeightminimum weightprns:numberOfAuthorsnumber of authorsprns:numberOfConnectionsnumber of connectionsprns:numberOfPublicationsnumber of publicationsprns:personIdPerson IDprns:personInPrimaryPositionperson in primary positionprns:physicalNeighborOfphysical neighborprns:pluginSearchableDataProfilesRNS Plugin Searchable Dataprns:positionInDepartmentposition in departmentprns:predicateNodepredicate nodeprns:publicationDatepublication dateprns:similarTosimilar toprns:sortOrdersort orderprns:trainingAtOrganizationeducational organizationprns:trainingLocationtraining locationprns:uniquenessWeightuniqueness weightprns:yearyearAcademic ArticleArticleDocumentbibo:pmidPubMed IdentifierAddressvivo:addressCitycityvivo:addressPostalCodepostal codevivo:addressStatestate or provincevivo:authorInAuthorshipselected publicationsvivo:authorRankauthor rank in publicationAuthorshipvivo:degreeEarneddegree earnedDepartmentvivo:educationalTrainingeducation and trainingEducational Trainingvivo:hasResearchArearesearch areasvivo:hrJobTitleHR job titleInformation Resourcevivo:linkedAuthorlinked authorvivo:linkedInformationResourcelinked information resourcevivo:mailingAddressmailing addressvivo:majorFieldmajor field of degreevivo:personInPositionpositionsPositionvivo:positionInOrganizationposition in organizationvivo:preferredTitlepreferred titlerdf:predicatepredicaterdf:typetyperdfs:labellabelConceptAgentfoaf:firstNamefirst namefoaf:lastNamelast nameOrganizationPersonD001650Disorders40790.909473Bile Duct NeoplasmsChicago60637IL1.132970.020423683research areas1.367040.04690152coauthor of22.64882.7204460similar to1120selected publicationsOsmanuddinAhmedOsmanuddin Ahmed41.7886000000000087.598699999999993682Ahmed, OsmanuddinAssociate ProfessorMedicine-GastroenterologySurgery-General SurgeryXavierKeutgenz2lsHrUSHOL5hHlsaUXv9Gq0+s+oXavier Keutgen41.7886000000000087.598699999999993746Keutgen, XavierAssociate Professor06/2006University of California, BerkeleyBerkeley, CAUniversity of California, Berkeley, Molecular & Cell Biology -- GeneticsBAMolecular & Cell Biology -- Genetics06/2011Vanderbilt University School of MedicineNashville, TNVanderbilt University School of Medicine, MedicineMDMedicine06/2014Rush University Medical CenterChicago, ILRush University Medical Center, Internal Medicine ResidencyInternal Medicine Residency06/2017Washington University in St. LouisSt. Louis, MOWashington University in St. Louis, Hematology/Oncology FellowshipHematology/Oncology FellowshipAuthorship 1357702132058557Catenacci DVT, Chase L, Lomnicki S, Karrison T, de Wilton Marsh R, Rampurwala MM, Narula S, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Peterson B, Moore K, Kipping-Johnson K, Markevicius U, Gordon B, Allen K, Racette C, Maron SB, Liao CY, Polite BN, Kindler HL, Turaga K, Prachand VN, Roggin KK, Ferguson MK, Posner MCJAMA network openEvaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial. JAMA Netw Open. 2020 02 05; 3(2):e1921290.JAMA Netw Open2020-02-05T00:00:002020Evaluation of the Association of Perioperative UGT1A1 Genotype-Dosed gFOLFIRINOX With Margin-Negative Resection Rates and Pathologic Response Grades Among Patients With Locally Advanced Gastroesophageal Adenocarcinoma: A Phase 2 Clinical Trial.Authorship 137829632446596Vaghaiwalla T, Ruhle B, Memeh K, Angelos P, Kaplan E, Liao CY, Polite B, Keutgen XSurgeryResponse rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies. Surgery. 2021 01; 169(1):162-167.Surgery2020-05-20T00:00:002020Response rates in metastatic neuroendocrine tumors receiving peptide receptor radionuclide therapy and implications for future treatment strategies.AdamDuVallAdam DuVall41.7886000000000087.598699999999993963DuVall, AdamAssistant Professor32892267Berger Y, Schuitevoerder D, Vining CC, Alpert L, Fenton E, Hindi E, Liao CY, Shergill A, Catenacci DVT, Polite BN, Eng OS, Turaga KKAnnals of surgical oncologyNovel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma. Ann Surg Oncol. 2021 Mar; 28(3):1777-1785.Ann Surg Oncol2020-09-05T00:00:002020Novel Application of Iterative Hyperthermic Intraperitoneal Chemotherapy for Unresectable Peritoneal Metastases from High-Grade Appendiceal Ex-Goblet Adenocarcinoma.Authorship 140724733234578Catenacci DVT, Moya S, Lomnicki S, Chase LM, Peterson BF, Reizine N, Alpert L, Setia N, Xiao SY, Hart J, Siddiqui UD, Hogarth DK, Eng OS, Turaga K, Roggin K, Posner MC, Chang P, Narula S, Rampurwala M, Ji Y, Karrison T, Liao CY, Polite BN, Kindler HLCancer discoveryPersonalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease. Cancer Discov. 2021 02; 11(2):308-325.Cancer Discov2020-11-24T00:00:002020Personalized Antibodies for Gastroesophageal Adenocarcinoma (PANGEA): A Phase II Study Evaluating an Individualized Treatment Strategy for Metastatic Disease.Authorship 14221622Authorship 142610333299111Dolezal JM, Trzcinska A, Liao CY, Kochanny S, Blair E, Agrawal N, Keutgen XM, Angelos P, Cipriani NA, Pearson ATModern pathology : an official journal of the United States and Canadian Academy of Pathology, IncDeep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features. Mod Pathol. 2021 05; 34(5):862-874.Mod Pathol2020-12-10T00:00:002020Deep learning prediction of BRAF-RAS gene expression signature identifies noninvasive follicular thyroid neoplasms with papillary-like nuclear features.Authorship 143135833420565Berger Y, Giurcanu M, Vining CC, Schuitevoerder D, Posner MC, Roggin KK, Polite BN, Liao CY, Eng OS, Catenacci DVT, Turaga KKAnnals of surgical oncologyCytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy. Ann Surg Oncol. 2021 Aug; 28(8):4433-4443.Ann Surg Oncol2021-01-08T00:00:002021Cytoreductive Surgery for Selected Patients Whose Metastatic Gastric Cancer was Treated with Systemic Chemotherapy.Medicine-Hematology and OncologyRadiology-Vascular/Interventional Radiology34168049Foster CC, Fleming GF, Karrison TG, Liao CY, Desai AV, Moroney JW, Ratain MJ, Nanda R, Polite BN, Hahn OM, O'Donnell PH, Vokes EE, Kindler HL, Hseu R, Janisch LA, Dai J, Hoffman MD, Weichselbaum RR, Pitroda SP, Chmura SJ, Luke JJClinical cancer research : an official journal of the American Association for Cancer ResearchPhase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors. Clin Cancer Res. 2021 10 15; 27(20):5510-5518.Clin Cancer Res2021-06-24T00:00:002021Phase I Study of Stereotactic Body Radiotherapy plus Nivolumab and Urelumab or Cabiralizumab in Advanced Solid Tumors.DanielOlsonDaniel Olson41.7886000000000087.598699999999994056Olson, DanielAssistant ProfessorD018281Disorders33660.925903CholangiocarcinomaAuthorship 1499454Authorship 1519671234988836Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KKAnnals of surgical oncologyPhase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Jan 05.Ann Surg Oncol2022-01-05T00:00:002022Phase II Prospective, Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy With and Without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor Deoxyribose Nucleic Acid (ctDNA) Levels.Authorship 153060735171113Lakiza O, Lutze J, Vogle A, Williams J, Abukdheir A, Miller P, Liao C', Pitroda SP, Martinez C, Olivas A, Setia N, Kron SJ, Weichselbaum RR, Keutgen XMEndocrine-related cancerLoss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors. Endocr Relat Cancer. 2022 03 21; 29(4):225-239.Endocr Relat Cancer2022-03-21T00:00:002022Loss of MEN1 function impairs DNA repair capability of pancreatic neuroendocrine tumors.Authorship 154456435504360Kent J, Erwin P, Haraf D, Liao CY, Durham J, Angelos P, Agrawal N, Baird BJ, Madariaga MLLThe Annals of thoracic surgeryLaryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma. Ann Thorac Surg. 2023 05; 115(5):e117-e120.Ann Thorac Surg2022-04-30T00:00:002022Laryngotracheal Resection After B-Raf Proto-oncogene Inhibition for Anaplastic Thyroid Carcinoma.FrederickHowardFrederick Howard41.7886000000000087.598699999999994166Howard, FrederickAssistant ProfessorD013274Disorders962660.789027Stomach NeoplasmsAuthorship 15823512Authorship 1588353Authorship 1593216Authorship 1594371336108891Juloori A, Katipally RR, Lemons JM, Singh AK, Iyer R, Robbins JR, George B, Hall WA, Pitroda SP, Arif F, Fung J, Pillai A, Liao CY, Sharma M, Liauw SLInternational journal of radiation oncology, biology, physicsPhase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma. Int J Radiat Oncol Biol Phys. 2023 01 01; 115(1):202-213.Int J Radiat Oncol Biol Phys2022-09-13T00:00:002022Phase 1 Randomized Trial of Stereotactic Body Radiation Therapy Followed by Nivolumab plus Ipilimumab or Nivolumab Alone in Advanced/Unresectable Hepatocellular Carcinoma.36163102Fung J, DiSabato D, Liao CY, Ahmed O, Pillai AHepatobiliary & pancreatic diseases international : HBPD INTPerspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology. Hepatobiliary Pancreat Dis Int. 2023 02; 22(1):4-6.Hepatobiliary Pancreat Dis Int2022-09-09T00:00:002022Perspective: Advances in liver transplantation for hepatocellular carcinoma - A prototype for transplant oncology.36521794Ahmed O, Yu Q, Patel M, Hwang G, Pillai A, Liao CY, Fung J, Baker TJournal of vascular and interventional radiology : JVIRYttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma. J Vasc Interv Radiol. 2023 04; 34(4):702-709.J Vasc Interv Radiol2022-12-13T00:00:002022Yttrium-90 Radioembolization and Concomitant Systemic Gemcitabine, Cisplatin, and Capecitabine as the First-Line Therapy for Locally Advanced Intrahepatic Cholangiocarcinoma.35930113Dhiman A, Vining CC, Witmer HDD, Sood D, Shergill A, Kindler H, Roggin KK, Posner MC, Ahmed OS, Liauw S, Pitroda S, Liao CY, Karrison T, Weichselbaum R, Polite B, Eng OS, Catenacci DVT, Turaga KKAnnals of surgical oncologyASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels. Ann Surg Oncol. 2022 Dec; 29(Suppl 3):616-617.Ann Surg Oncol2022-12-01T00:00:002022ASO Visual Abstract: Phase II Prospective Open-Label Randomized Controlled Trial Comparing Standard of Care Chemotherapy with and without Sequential Cytoreductive Interventions for Patients with Oligometastatic Foregut Adenocarcinoma and Undetectable Circulating Tumor-Deoxyribose Nucleic Acid (ctDNA) Levels.Authorship 160819436739162Schwarz JL, Williams JK, Keutgen XM, Liao CYSurgical pathology clinicsLight It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms. Surg Pathol Clin. 2023 Mar; 16(1):151-161.Surg Pathol Clin2022-12-13T00:00:002022Light It Up! The Use of DOTATATE in Diagnosis and Treatment of Neuroendocrine Neoplasms.D00007207852860.92056Positron Emission Tomography Computed Tomography@TheRealDoctorOsAuthorship 162141237182801Rosenberg AJ, Liao CY, Karrison T, de Souza JA, Worden FP, Libao B, Krzyzanowska MK, Hayes DN, Winquist E, Saloura V, Prescott K, Villaflor VM, Seiwert TY, Schechter RB, Stadler WM, Cohen EEW, Vokes EEAnnals of oncology : official journal of the European Society for Medical OncologyA multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer. Ann Oncol. 2023 08; 34(8):714-722.Ann Oncol2023-05-13T00:00:002023A multicenter, open-label, randomized, phase II study of cediranib with or without lenalidomide in iodine 131-refractory differentiated thyroid cancer.D018358Disorders401050.856231Neuroendocrine TumorsJamesDolezalJames Dolezal41.7886000000000087.598699999999994332Dolezal, JamesInstructorMedicineSurgeryUniversity of ChicagoMitchell C.PosnerMitchell C. Posner41.78927490000000-87.601250000000001115Posner, Mitchell C.ProfessorJosephFransesJoseph Franses41.7886000000000087.598699999999994435Franses, JosephAssistant Professor37532096Yu Q, Patel M, Kwak D, Ungchusri E, Wang Y, Van Ha T, Zangan S, Marshall E, Little K, Baker T, Liao CY, Pillai A, Ahmed OJournal of vascular and interventional radiology : JVIRSegmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience. J Vasc Interv Radiol. 2023 11; 34(11):1970-1976.e1.J Vasc Interv Radiol2023-08-01T00:00:002023Segmental Yttrium-90 Radioembolization Using Glass Microspheres Greater than 400 Gray for the Treatment of Intrahepatic Cholangiocarcinoma: A Preliminary Experience.Authorship 16598311Authorship 167053437812295Yu Q, Ungchusri E, Pillai A, Liao CY, Baker T, Fung J, DiSabato D, Zhang M, Liao C, Van Ha T, Ahmed OEuropean radiologySelective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma. Eur Radiol. 2024 Apr; 34(4):2374-2383.Eur Radiol2023-10-09T00:00:002023Selective internal radiation therapy using yttrium-90 microspheres for treatment of localized and locally advanced intrahepatic cholangiocarcinoma.HedyKindler32lgBaUZHP75hHlsaUXv9Gq0+s+oHedy Kindler41.78927490000000-87.601250000000002499Kindler, HedyProfessorYusukeNakamuraYusuke Nakamura41.78927490000000-87.60125000000000582Nakamura, YusukeEmeritus/Emerita, ProfessorAuthorship 169985838312131Yu Q, Wang Y, Ungchusri E, Patel M, Kumari D, Van Ha T, Pillai A, Liao CY, Ahmed OJournal of interventional medicineCombination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility. J Interv Med. 2023 Nov; 6(4):187-193.J Interv Med2023-09-28T00:00:002023Combination of transarterial radioembolization with atezolizumab and bevacizumab for intermediate and advanced staged hepatocellular carcinoma: A preliminary report of safety and feasibility.Authorship 170882538490364Yu Q, Wang Y, Ungchusri E, Pillai A, Liao CY, Fung J, DiSabato D, Baker T, Patel M, Van Ha T, Ahmed OJournal of vascular and interventional radiology : JVIRModified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors. J Vasc Interv Radiol. 2024 Mar 13.J Vasc Interv Radiol2024-03-13T00:00:002024Modified Radiation Lobectomy Strategy of Radioembolization for Right-Sided Unresectable Primary Liver Tumors.true1Emeritus/Emerita, ProfessorEmeritus/Emerita, Professortrue1Associate ProfessorAssociate Professortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1InstructorInstructortrue1Assistant ProfessorAssistant Professortrue1Assistant ProfessorAssistant Professortrue1ProfessorProfessortrue1Assistant ProfessorAssistant Professortrue1Associate ProfessorAssociate Professortrue1ProfessorProfessortrue1Associate ProfessorAssociate Professor1010AnjanaPillaiAnjana Pillai0.000000000000000.000000000000003399Pillai, AnjanaAssociate Professor